GEN-MKT-18-7897-A
Feb 7, 2025 | Blogs, Pharma, ZenoTOF 7600 system | 0 comments
Read Time: 2 Minutes
Liquid chromatography-mass spectrometry is commonly used for Met ID but confident soft spot identification is not always possible. Imagine the advantage of unambiguous metabolite identification using liquid chromatography-mass spectrometry (LC-MS) reducing the need for additional safety testing during drug discovery. Quickly and easily generate the information you need using routine assays that are robust and efficient, enabling confident decision-making while also saving time and money. Learn more >
Metabolite identification is a key task during drug discovery to establish safety and efficacy of a drug candidate. LC-MS assays for metabolite identification typically use collision-induced dissociation (CID) to fragment ions for structural elucidation, and soft-spot identification. With challenging metabolites, CID doesn’t produce sufficient fragment ions or help with labile modifications and a clear identification cannot be made. This can lead to the need for additional testing to meet regulatory requirements.
EAD is a fragmentation method available on the ZenoTOF 7600 system that causes ions in an LC-MS/MS experiment to fragment in locations that are different from where they fragment with CID, providing additional information to scientists. For metabolite identification, this could mean confident identification of the metabolite and localization of the site of metabolism, removing the need for additional safety testing.
Curious to know more? Watch our on-demand Met ID webinars, here? LINK WILL COME FROM HERE https://sciex.kapost.com/posts/pharma-webinar-content-hub-lp-and-typ
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network